Heart Failure with Preserved Ejection Fraction Treatment Study
Evaluating Metabolic Mechanisms of Ertugliflozin in Non-Diabetes Heart Failure with Preserved Ejection Fraction
HEALTHY PARTICIPANTS: No
CONDITION: Heart Disease
The main purpose of this study is to investigate the effectiveness of ertugliflozin (a pill that lowers glucose levels) therapy to alter the heart’s metabolism to positively impact heart health and function in treating subjects with a type of chronic (long term) heart failure (HF) called heart failure with preserved ejection fraction (HFpEF).
Who Can Participate
Individuals between 18 and 75 years old who have not been hospitalized for heart failure within 6 months may be eligible for this study.